MYC and gastric cancer: Tepotinib treatment decreased EMT-promoting genes such as MUC5B, MMP7, MMP9, COX-2, WNT1, CCND1, and c-MYC and increased EMT-suppressing genes such as MUC5AC, MUC6, GSK3β, and ECAD in c-MET-amplified GC cells (Figure 4a).